talfirastide
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
DMD-Associated Dilated Cardiomyopathy
Conditions
DMD-Associated Dilated Cardiomyopathy
Trial Timeline
Aug 31, 2023 → Dec 1, 2024
NCT ID
NCT06013839About talfirastide
talfirastide is a phase 2 stage product being developed by Constant Therapeutics for DMD-Associated Dilated Cardiomyopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT06013839. Target conditions include DMD-Associated Dilated Cardiomyopathy.
Hype Score Breakdown
Clinical
12
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06013839 | Phase 2 | UNKNOWN |